{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:24:38Z","timestamp":1791336278135,"version":"4.3.1"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>It is not clear if long-term antithrombotic treatment has a beneficial effect on the incidence of thromboembolism in chronic heart failure (CHF). The HELAS study (Heart failure Long-term Antithrombotic Study) is a multicentre, randomised, double-blind, placebo-controlled trial to evaluate antithrombotic treatment in patients with CHF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>197 HF patients (EF &amp;lt;35%) were enrolled. Patients with Ischaemic Heart Disease were randomised to receive either aspirin 325 mg or warfarin. Patients with Dilated Cardiomyopathy (DCM) were randomised to receive either warfarin or placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Analysis of the data from 312 patient years showed an incidence of 2.2 embolic events per 100 patient years, with no significant difference between groups. The incidence of myocardial infarction, hospitalisation, exacerbation of heart failure, death and haemorrhage were not different between the groups. No peripheral or pulmonary emboli were reported. Echocardiographic follow-up for 2 years showed an overall increase in left ventricular ejection fraction from 28.2\u00b16 to 30.3\u00b17 p&amp;lt;0.05, which was most obvious in patients with DCM taking warfarin (EF 26.8\u00b15.3 at baseline, 30.7\u00b110 at 2 years, p&amp;lt;0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>(1) Overall embolic events are rare in heart failure regardless of treatment. (2) Treatment does not seem to affect outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.ejheart.2006.02.012","type":"journal-article","created":{"date-parts":[[2006,6,6]],"date-time":"2006-06-06T23:34:33Z","timestamp":1149636873000},"page":"428-432","source":"Crossref","is-referenced-by-count":190,"title":["Efficacy of Antithrombotic Therapy in Chronic Heart Failure: The HELAS Study"],"prefix":"10.1093","volume":"8","author":[{"given":"Dennis V.","family":"Cokkinos","sequence":"first","affiliation":[{"name":"Cardiology Department, Hippokrateio Hospital, University of Athens , Athens ,","place":["Greece"]},{"name":"1st Cardiology Department, Onassis Cardiac Surgery Center , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George C.","family":"Haralabopoulos","sequence":"additional","affiliation":[{"name":"1st Cardiology Department, Onassis Cardiac Surgery Center , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Kostis","sequence":"additional","affiliation":[{"name":"UMDNJ-Robert Wood Johnson Medical School , New Brunswick ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos K.","family":"Toutouzas","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hippokrateio Hospital, University of Athens , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the HELAS investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,6,11]]},"reference":[{"key":"2026020203523406900_ejhf2006-02-012-bib-0001","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00001573-199705000-00009","article-title":"Anticoagulant and antiplatelet therapy in heart failure","volume":"12","author":"Cleland","year":"1997","journal-title":"Curr Opin Cardiol"},{"key":"2026020203523406900_ejhf2006-02-012-bib-0002","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure","volume":"325","author":"The SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"2026020203523406900_ejhf2006-02-012-bib-0003","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"The CONSENSUS Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"key":"2026020203523406900_ejhf2006-02-012-bib-0004","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJM199701233360403","article-title":"Ventricular dysfunction and the risk of stroke after myocardial infarction","volume":"336","author":"Loh","year":"1997","journal-title":"N Engl J Med"},{"key":"2026020203523406900_ejhf2006-02-012-bib-0005","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/oxfordjournals.eurheartj.a015073","article-title":"Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients","volume":"17","author":"Cioffi","year":"1996","journal-title":"Eur Heart J"},{"key":"2026020203523406900_ejhf2006-02-012-bib-0006","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1054\/jcaf.2002.31907","article-title":"Anticoagulation in patients with dilated cardiomyopathy and sinus rhythm: A critical literature review","volume":"8","author":"Sirajuddin","year":"2002","journal-title":"J Card Fail"},{"key":"2026020203523406900_ejhf2006-02-012-bib-0007","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ahj.2004.03.010","article-title":"The warfarin\/aspirin study in heart failure (WASH): A randomized trial comparing antithrombotic strategies for patients with heart failure","volume":"148","author":"Cleland","year":"2004","journal-title":"Am Heart J"},{"key":"2026020203523406900_ejhf2006-02-012-bib-0008","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ejheart.2004.04.014","article-title":"Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO LIPIDS and cardiac resynchronisation therapy in heart failure","volume":"6","author":"Cleland","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"2026020203523406900_ejhf2006-02-012-bib-0009","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/eurheartj\/ehi204","article-title":"Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)","volume":"26","author":"The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology","year":"2005","journal-title":"Eur Heart J"},{"key":"2026020203523406900_ejhf2006-02-012-bib-0010","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1388-9842(99)00055-0","article-title":"Antithrombotic therapy in heart failure: a randomized comparison of warfarin vs aspirin","volume":"1","author":"Cokkinos","year":"1999","journal-title":"Eur J Heart Fail"},{"key":"2026020203523406900_ejhf2006-02-012-bib-0011","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0735-1097(97)00019-3","article-title":"Ejection fraction and risk of thromboembolism events in patients with systolic dysfunction and sinus rhythm. Evidence for gender differences in the studies of left ventricular dysfunction trial","volume":"29","author":"Dries","year":"1997","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"2026020203523406900_ejhf2006-02-012-bib-0012","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/archinte.163.13.1574","article-title":"Aspirin-angiotensin converting enzyme inhibitor coadministration and mortality in patients with heart failure and dose-related adverse effects of aspirin","volume":"163","author":"Guazzi","year":"2003","journal-title":"Arch Intern Med"},{"key":"2026020203523406900_ejhf2006-02-012-bib-0013","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/hrt.74.3.215","article-title":"Is aspirin safe for patients with heart failure?","volume":"74","author":"Cleland","year":"1995","journal-title":"Br Heart J"},{"key":"2026020203523406900_ejhf2006-02-012-bib-0014","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1053\/pcad.2002.31597","article-title":"Is aspirin \u201cthe weakest link\u201d in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease","volume":"44","author":"Cleland","year":"2002","journal-title":"Prog Cardiovasc Dis"},{"key":"2026020203523406900_ejhf2006-02-012-bib-0015","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0140-6736(02)11138-X","article-title":"Effects of long-term treatment with angiotensin converting enzyme inhibitors in the presence or absence of aspirin: a systematic review","volume":"360","author":"Teo","year":"2002","journal-title":"Lancet"},{"issue":"7","key":"2026020203523406900_ejhf2006-02-012-bib-0016","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1046\/j.1532-5415.2002.50305.x","article-title":"Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors on health outcomes of very old patients with heart failure?","volume":"50","author":"Lapane","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"2026020203523406900_ejhf2006-02-012-bib-0017","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0735-1097(98)00006-0","article-title":"Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction","volume":"31","author":"Al-Khadra","year":"1998","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ejheart.2006.02.012","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/8\/4\/428\/66617920\/eurjhf_8_4_428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/8\/4\/428\/66617920\/eurjhf_8_4_428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:52:42Z","timestamp":1770022362000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/8\/4\/428\/8443886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,1]]},"references-count":17,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2006,6,11]]},"published-print":{"date-parts":[[2006,6,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ejheart.2006.02.012","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,6]]},"published":{"date-parts":[[2006,6,1]]}}}